Reduced levels of serum EPA and DHA identified in patients with non-small-cell lung cancer using a new rapid validated LC-MS/MS method

SLAS Discovery: Advancing the Science of Drug Discovery Pub Date : 2023-12-13 DOI:10.1016/j.slasd.2023.12.006

Yi Wang, Tongxin Yin, Jiaoyuan Li, Xia Luo, Ke Liu, Tingting Long, Ying Shen, Liming Cheng

{"title":"Reduced levels of serum EPA and DHA identified in patients with non-small-cell lung cancer using a new rapid validated LC-MS/MS method","authors":"Yi Wang, Tongxin Yin, Jiaoyuan Li, Xia Luo, Ke Liu, Tingting Long, Ying Shen, Liming Cheng","doi":"10.1016/j.slasd.2023.12.006","DOIUrl":null,"url":null,"abstract":"Background: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been suggested to play roles in various diseases, yet there is little data on their changes in patients with non-small-cell lung cancer (NSCLC). A simple LC-MS/MS method for EPA and DHA determination is critical to exploring EPA and DHA level changes in NSCLC patients.Method: 25 μL of serum was mixed with 25 μL of internal standard working solution, and then 450 μL of acetonitrile for protein precipitation. After vortex and centrifugation, the supernatant was directly used for LC-MS/MS analysis. The method was well validated with linearity, precision, recovery, and matrix effect. The concentrations of EPA and DHA in serum samples from 211 NSCLC patients and 227 healthy controls were determined by this LC-MS/MS method.Results: Good separation and reliable quantification of EPA and DHA in serum samples were achieved by our method. Compared with healthy controls, serum EPA and DHA were significantly reduced in both adenocarcinoma and squamous cell carcinoma. The concentrations of EPA and DHA showed a progressive decrease in healthy controls, early- and advanced-stage NSCLC patients.Conclusions: This study identified significant reductions in serum EPA and DHA in NSCLC patients through the development of an LC-MS/MS method.","PeriodicalId":501832,"journal":{"name":"SLAS Discovery: Advancing the Science of Drug Discovery","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Discovery: Advancing the Science of Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.slasd.2023.12.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been suggested to play roles in various diseases, yet there is little data on their changes in patients with non-small-cell lung cancer (NSCLC). A simple LC-MS/MS method for EPA and DHA determination is critical to exploring EPA and DHA level changes in NSCLC patients.

Method: 25 μL of serum was mixed with 25 μL of internal standard working solution, and then 450 μL of acetonitrile for protein precipitation. After vortex and centrifugation, the supernatant was directly used for LC-MS/MS analysis. The method was well validated with linearity, precision, recovery, and matrix effect. The concentrations of EPA and DHA in serum samples from 211 NSCLC patients and 227 healthy controls were determined by this LC-MS/MS method.

Results: Good separation and reliable quantification of EPA and DHA in serum samples were achieved by our method. Compared with healthy controls, serum EPA and DHA were significantly reduced in both adenocarcinoma and squamous cell carcinoma. The concentrations of EPA and DHA showed a progressive decrease in healthy controls, early- and advanced-stage NSCLC patients.

Conclusions: This study identified significant reductions in serum EPA and DHA in NSCLC patients through the development of an LC-MS/MS method.

查看原文本刊更多论文

利用新型快速验证 LC-MS/MS 方法确定非小细胞肺癌患者血清 EPA 和 DHA 水平降低的原因

背景：二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）被认为在多种疾病中发挥作用，但有关它们在非小细胞肺癌（NSCLC）患者体内变化的数据却很少。方法：将 25 μL 血清与 25 μL 内标工作液混合，然后用 450 μL 乙腈沉淀蛋白质。涡旋离心后，上清液直接用于 LC-MS/MS 分析。该方法的线性、精密度、回收率和基质效应均得到了良好的验证。采用该 LC-MS/MS 方法测定了 211 例 NSCLC 患者和 227 例健康对照者血清样本中 EPA 和 DHA 的浓度：结果：我们的方法实现了血清样品中EPA和DHA的良好分离和可靠定量。与健康对照组相比，腺癌和鳞癌患者血清中的 EPA 和 DHA 均明显减少。在健康对照组、早期和晚期 NSCLC 患者中，EPA 和 DHA 的浓度呈逐渐下降趋势：本研究通过开发一种 LC-MS/MS 方法，确定了 NSCLC 患者血清中 EPA 和 DHA 的显著降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SLAS Discovery: Advancing the Science of Drug Discovery

自引率

0.00%

发文量